Elsevier

The Lancet

Volume 364, Issue 9431, 24–30 July 2004, Pages 365-367
The Lancet

Fast track — Research Letters
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

https://doi.org/10.1016/S0140-6736(04)16725-1Get rights and content

Summary

The meningococcal serogroup C conjugate (MCC) vaccine programme in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years). However, for children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vaccine fell to low levels after only 1 year. The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.

References (7)

There are more references available in the full text version of this article.

Cited by (516)

  • Carbohydrate-based anti-bacterial and anti-cancer vaccines

    2020, Carbohydrates in Drug Discovery and Development: Synthesis and Application
View all citing articles on Scopus
View full text